Can Pfizer's new Crohn's data help Inflectra pry away Remicade market share?
admin 30th October 2017 Uncategorised 0Pfizer, which is struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales for its Inflectra.
More: Can Pfizer's new Crohn's data help Inflectra pry away Remicade market share?
Source: fierce